Views & Analysis Coming of age: Alnylam and the RNAi revolution Alynylam has a crucial two years ahead of it, but it and RNAi could be about to come of age.
News Circassia shares plummet following cat allergy therapy failu... Company said the failure could have implications for its other products under development
News Biogen eyeing big-selling biosimilars as MS drug fails Gamble on opicinumab looks unlikely to pay off.
News FDA asks for more data on Sarepta's muscular dystrophy drug Regulator asks for more data from ongoing trial.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
